Normalization of peripheral blood cell composition by lactoferrin in cyclophosphamide-treated mice

Medical Science Monitor

Volumn 10, Issue 3, 2004, Pages

  Artym, Jolanta ^a   Zimecki, Michał ^a   Kruzel, Marian ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cyclophosphamide; Lactoferrin; Leukopenia; Mice; Reconstitution

Indexed keywords

CYCLOPHOSPHAMIDE; LACTOFERRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL; CELL TYPE; CONTROLLED STUDY; DRUG EFFECT; EOSINOPHILIA; FEMALE; IMMUNE DEFICIENCY; IMMUNITY; LEUKOCYTOSIS; LYMPHOCYTE; LYMPHOCYTOPENIA; MALE; MOUSE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PROTEIN FUNCTION;

ANIMALS; BODY WEIGHT; CYCLOPHOSPHAMIDE; EOSINOPHILS; IMMUNOSUPPRESSIVE AGENTS; LACTOFERRIN; LEUKOCYTOSIS; LYMPHOCYTES; LYMPHOPENIA; MICE; MICE, INBRED CBA; MYELOPOIESIS; NEUTROPENIA; NEUTROPHILS; TIME FACTORS;

EID: 1542511280     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Lacki JK, Mackiewicz SH, Leszczynski P, Muller W: The effect of intravenous cyclophosphamide pulse on peripheral blood lymphocytes in lupus erythematosus patients. Rheumatol Int, 1997; 17: 55-60
2. Mok CC, Ho CT, Chan KW et al: Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum, 2002; 46: 1003-13
3. Weiner HL, Cohen JA: Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler, 2002; 8: 142-54
4. Leandro MJ, Edwards JC, Cambridge G: Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Comment in: Ann Rheum Dis, 2002; 6: 863-66, Ann Rheum Dis, 2002; 61: 883-88
5. Leandro MJ, Edwards JC, Cambridge G: Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Comment in: Ann Rheum Dis, 2002; 6: 863-66, Ann Rheum Dis, 2002; 61: 883-88
6. Dabrowski A, Droszcz W: Wegener's granulomatosis - clinical analysis of 18 patients group. Med Sci Monit, 2000; 6: 151-57
7. Asou N, Suzushima H, Hishimura S et al: Long-term remission in an elderly patient with mantle cell leukemia treated with low-dose cyclophosphamide. Am J Haematol, 2000; 63: 35-37.
8. Shalit I, Kletter Y, Halperin D et al: Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia. Eur J Haematol, 2000; 66: 287-96
9. Vogels MT, Hermsen CC, Huys HL et al: Roles of tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, platelet-activating factor, and arachidonic acid metabolites in interleukin-1-induced resistance to infection in neutropenic mice. Infect Immun, 1994; 62: 2065-70
10. Anton E: Ultrastructural changes of stromal cells of bone marrow and liver after cyclophosphamide treatment in mice. Tissue Cell, 1997; 29: 1-9
11. Hemendinger RA, Bloom SE: Selective mitomycin C and cylophosphamide induction of apoptosis in differentiating B lymphocytes compared to T lymphocytes in vivo. Immunopharmacology, 1996; 35: 71-82
12. Fulcher DA, Basten A: B cell life span: a review. Immunol Cell Biol, 1997; 75: 446-55
13. Masnaya NV, Ratner GM: Peculiarities of primary humoral immune response in mice with cytostatic disease. Bull Exp Biol Med, 2000; 129: 370-73
14. Turk JL: Studies on the mechanism of action of methotrexate and cyclophosphamide on contact sensitivity in the guinea pig. Int Arch Allergy, 1964; 24: 191-200
15. Mu HH, Penny R, Sewell WA: Interleukin-5 is necessary for eosinophilia induced by cyclophosphamide in immunized mice. Immunology, 1993; 79: 452-58
16. Marcinkiewicz J, Bryniarski K, Ptak W: Cyclophosphamide uncovers two separate macrophage subpopulations with opposite immunogenic potential and different patterns of monokine production. Cytokine, 1994; 6: 472-77
17. Miyauchi A, Hiramine C, Tanaka S, Hojo K: Differential effects of a single dose of cyclophosphamide on T cell subsets of the thymus and spleen in mice: flow cytofluorometry analysis. Tohoku J Exp Med, 1990; 162: 147-67
18. Wang E, Simard M, Ouellet N et al: Pathogenesis of pneumococcal pneumonia in cyclophosphamide-induced leukopenia in mice. Infect Immun, 2002; 70: 4226-28
19. Correa EB, Cunha JM, Bunn-Moreno MM, Madeira ED: Cyclophosphamide affects the dynamics of granuloma formation in experimental visceral leishmaniasis. Parasitol Res, 1992; 78: 154-60
20. Ohmori H, Kamo M, Yamakoshi K et al: Restoration of immunocyte functions by thymosin alpha1 in cyclophosphamide-induced immunodeficient mice. Immunopharmacol Immunotoxicol, 2001; 23: 75-82
21. Fibbe WE, van der Meer JW, Falkenburg JH et al: A single low dose of human recombinant interleukin 1 accelerates the recovery of neutrophils in mice with cyclophosphamide-induced neutropenia. Exp Hematol, 1989; 17: 805-8
22. Santosuosso M, Divangahi M, Zganiacz A, Xing Z: Reduced tissue macrophage population in the lung by anticancer agent cyclophosphamide: restoration by local granulocyte macrophage colony-stimulating factor gene transfer. Blood, 2002; 99: 1246-52
23. Morrissey PJ, Conlon P, Braddy S et al: Administration of IL-7 to mice with cyclophosphamide-induced lymphopenia accelerates lymphocyte repopulation. J Immunol, 1991; 146: 1547-52
24. Kalechman Y, Sotnik-Barkai I, Albeck M, Sredni B: The effect of AS101 on the reconstitution of T-cell reactivity following irradiation or cyclophosphamide treatment. Exp Hematol, 1992; 20: 1302-8
25. Wang GL, Lin ZB: The immunomodulatory effect of lentinan. Yao Xue Xue Bao, 1996; 31: 86-90
26. Zaidi SI, Singh KP, Raisuddin S et al: Protein A induced abrogation of cyclophosphamide toxicity is associated with concomitant potentiation of immune function of host. Immunopharmacol Immunotoxicol, 1990; 12: 479-512
27. Lonnerdal B, Iyer S: Lactoferrin: molecular structure and biological function. Annu Rev Nutr, 1995; 15: 93-110
28. Ellison RT III, Giehl TJ, LaForce FM: Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect Immun, 1988; 56: 2774-81
29. Tomita M, Bellamy W, Takase M et al: Potent and bacterial peptides generated by pepsin digestion of bovine lactoferrin. J Dairy Sci, 1991; 74: 4137-42
30. Wakabayashi H, Abe S, Okutomi T et al: Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol Immunol, 1996; 40: 821-25
31. Sato R, Inanami O, Tanaka Y et al: Oral administration of bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency virus (FIV)-positive and FIV-negative cats. Am J Vet Res, 1996; 57: 1443-46
32. Yoo YC, Watanabe S, Watanabe R et al: Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res, 1997; 88: 184-90
33. Mazurier J, Legrand D, Hu WL et al: Expression of human lactotransferrin receptors in phytohemagglutinin-stimulated human peripheral blood lymphocytes. Isolation of the receptors by antiligand-affinity chromatography. Eur J Biochem, 1989; 179: 481-87
34. Hashizume S, Kuroda K, Murakami H: Identification of lactoferrin as an essential growth factor for human lymphocytic cell lines in serum-free medium. Biochim Biophys Acta, 1983; 763: 377-82
35. Birgens HS, Hansen NE, Karle H, Kristensen LO: Receptor binding of lactoferrin by human monocytes. Br J Haematol, 1983; 54: 383-91
36. Hu WL, Mazurier J, Montreuil J, Spik G: Isolation and partial characterization of a lactotransferrin receptor from mouse intestinal brush border. Biochemistry, 1990; 29: 535-41
37. Teraguchi S, Ozawa K, Yasuda S et al: The bacteriostatic effects of orally administered bovine lactoferrin on intestinal Enterobacteriaceae of SPF mice fed bovine milk. Biosci Biochim, 1994; 58: 482-87
38. Debbabi H, Dubarry M, Rautureau M, Tome D: Bovine lactoferrin induces both mucosal and systemic immune response in mice. J Dairy Res, 1998; 65: 283-93
39. Zimecki M, Mazurier J, Machnicki M et al: Immunostimulatory activity of lactotransferrin and maturation of CD4- CD8- murine thymocytes. Immunol Lett, 1991; 30: 119-23
40. Zimecki M, Mazurier J, Spik G, Kapp JA: Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology, 1995; 86: 122-27
41. Zimecki M, Spiegel K, Wlaszczyk A et al: Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells. Arch Immunol Ther Exp (Warsz), 1999; 47: 113-18
42. Bagby GC Jr, McCall E, Layman DL: Regulation of colony-stimulating activity production. Interactions of fibroblasts, mononuclear phagocytes, and lactoferrin. J Clin Invest, 1983; 71: 340-44
43. Rado TA, Bollekens J, St Laurent G et al: Lactoferrin biosynthesis during granulocytopoiesis. Blood, 1984; 64: 1103-9
44. Rich IN, Sawatzki G: Lactoferrin, the signal for colony stimulating factor production? Negative-feedback regulation versus supply-and-demand regulation of myelopoiesis. Blood Cells, 1989; 15: 400-6
45. Rich IN: The macrophage as a production site for hematopoietic regulator molecules: sensing and responding to normal and pathophysiological signals. Anticancer Res, 1988; 8: 1015-40
46. Artym J, Zimecki M, Kruzel ML: Reconstiuton of the cellular immune response by lactoferrin in cyclophosphamide-treated mice is correlated with renewal of T-cell compartment. Immunobiology, 2003; 207: 187-205
47. Tsuda H, Sekine K, Takasuka N et al: Prevention of colon carcinogenesis and carcinoma metastasis by orally administered bovine lactoferrin in animals. Biofactors, 2000; 12: 83-88
48. Zimecki M, Mazurier J, Spik G, Kapp JA: Lactoferrin inhibits proliferative response and cytokine production of TH1 but not TH2 cell lines. Arch Immunol Ther Exp (Warsz), 1996; 44: 51-56
49. th World Congress on Trauma, Shock, Inflammation and Sepsis, 2000 Feb 29 - Mar 4; Munich, Germany. Monduzzi Editore; 2000
50. Wlaszczyk A, Zimecki M, Adamik B et al: Immunological status of patients subjected to cardiac surgery: effect of lactoferrin on proliferation and production of interleukin 6 and tumor necrosis factor alpha by peripheral blood mononuclear cells in vitro. Arch Immunol Ther Exp (Warsz), 1997; 45: 201-12
51. Hilbert DM, Cancro MP, Scherle et al: T cell derived IL-6 is differentially required for antigen-specific antibody secretion by primary and secondary B cells. J Immunol, 1989; 143: 4019-24
52. Tsuda H, Sekine K, Fujita K, Ligo M: Cancer prevention by bovine lactoferrin and underlying mechanisms - a review of experimental and clinical studies. Biochem Cell Biol, 2002; 80: 131-36
53. Czerwionka-Szaflarska M, Chrobot A, Szaflarska-Szczepanik A: Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children. Med Sci Monit, 2000; 6: 964-70
54. Zimecki M, Wlaszczyk A, Wojciechowski R et al: Lactoferrin regulates the immune responses in post-surgical patients. Arch Immunol Ther Exp. (Warsz), 2001; 49: 325-33
55. Leszek J, Inglot AD, Janusz M, Byczkiewicz F et al: Colostrinin proline-rich polypeptide complex from ovine colostrum - a long-term study of its efficacy in Alzheimer's disease. Med Sci. Monit, 2002; 8: PI93-96